Evidence map›Paper›PMID 28992169›Full record

ReviewRheumatology (Oxford, England)2017

Points to consider when doing a trial primarily involving the heart.

Yannick Allanore, Oliver Distler, Ulrich A Walker, Dinesh Khanna, Daniel E Furst, Christophe Meune

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Rheumatology (Oxford, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Assessment of myocardial fibrosis in patients with systemic sclerosis using [European journal of nuclear medicine and molecular imaging · 2023
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yannick AllanoreDepartment of Rheumatology A, Cochin Hospital and Cochin Institute, AP-HP, Paris-Descartes University, Paris, France.
Oliver DistlerDepartment of Rheumatology, University Hospital Zurich, Zurich.
Ulrich A WalkerRheumatology Department, University of Basel, Basel, Switzerland.
Dinesh KhannaDepartment of Medicine, University of Michigan, University of Michigan Scleroderma Program, Ann Arbor, MI.
Daniel E FurstDepartment of Rheumatology, David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA, USA.
Christophe MeuneDepartment of Cardiology, Cochin Hospital, AP-HP, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac involvement contributes to the severity of SSc and should carefully be investigated and managed in SSc patients. Although it is commonly sub-clinical, once symptomatic it has a poor prognosis. Several complementary tools (circulating biomarkers, electrocardiography, echocardiography, scintigraphy or MRI) allow the assessment of all the various cardiac structures (endocardium, myocardium and pericardium) and heart function. Treatment remains empirical but cardiac trials in SSc can add data to the treatment of this complication.

Indexed as

CardiomyopathiesClinical Trials as TopicDisease ManagementEchocardiographyElectrocardiographyHumansScleroderma, Systemicarrhythmiacardiac fibrosisheartheart failuremyocarditispericarditissystemic sclerosis

Identifiers

PMID28992169
PMCPMC5850499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.